drugset / Trial / NCT04435483
A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is being conducted to support the clinical development of acalabrutinib in patients who are unable to swallow capsule and require nasogastric (NG) tube placement.
Timeline
- Start
- 2020-05-22
- Primary completion
- 2020-06-26
- Completion
- 2020-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acalabrutinib | Small molecule | 100 mg | Other |
| Subject | Rabeprazole | Small molecule | 20 mg | — |
Indications
No indication recorded.